Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: the HERA Trial.
about
Trastuzumab containing regimens for early breast cancerHER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneityQuantification of HER family receptors in breast cancerImpact of updated HER2 testing guidelines in breast cancer--re-evaluation of HERA trial fluorescence in situ hybridization data.Poor efficacy response to trastuzumab therapy in advanced gastric cancer with homogeneous HER2 positive and non-intestinal type.Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.Concomitant detection of HER2 protein and gene alterations by immunohistochemistry (IHC) and silver enhanced in situ hybridization (SISH) identifies HER2 positive breast cancer with and without gene amplificationHER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial.Pathological complete response and survival according to the level of HER-2 amplification after trastuzumab-based neoadjuvant therapy for breast cancer.Optimization of personalized therapies for anticancer treatmentSISH/CISH or qPCR as alternative techniques to FISH for determination of HER2 amplification status on breast tumors core needle biopsies: a multicenter experience based on 840 cases.Phase II trial of weekly nab-paclitaxel and carboplatin treatment with or without trastuzumab as nonanthracycline neoadjuvant chemotherapy for locally advanced breast cancer.Hybridization for human epidermal growth factor receptor 2 testing in gastric carcinoma: a comparison of fluorescence in-situ hybridization with a novel fully automated dual-colour silver in-situ hybridization method.Optimal systemic therapy for early breast cancer in women: a clinical practice guidelineKi-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical reviewTIRF high-content assay development for the evaluation of drug efficacy of chemotherapeutic agents against EGFR-/HER2-positive breast cancer cell lines.Association of HER-2 copy number and HER-2/CEP-17 ratio with neoadjuvant taxane-containing chemotherapy sensitivity in locally advanced breast cancerHER2/CEP17 Ratios and Clinical Outcome in HER2-Positive Early Breast Cancer Undergoing Trastuzumab-Containing Therapy.The relationship between quantitative human epidermal growth factor receptor 2 gene expression by the 21-gene reverse transcriptase polymerase chain reaction assay and adjuvant trastuzumab benefit in Alliance N9831.High HER2/Centromeric Probe for Chromosome 17 Fluorescence In Situ Hybridization Ratio Predicts Pathologic Complete Response and Survival Outcome in Patients Receiving Neoadjuvant Systemic Therapy With Trastuzumab for HER2-Overexpressing Locally AdvQuantification of HER2 heterogeneity in breast cancer-implications for identification of sub-dominant clones for personalised treatmentHER2 and ESR1 mRNA expression levels and response to neoadjuvant trastuzumab plus chemotherapy in patients with primary breast cancerHigh HER2 protein levels correlate with increased survival in breast cancer patients treated with anti-HER2 therapy.HER story: the next chapter in HER-2-directed therapy for advanced breast cancer.Overview of diagnostic/targeted treatment combinations in personalized medicine for breast cancer patients.A proposal for integrated efficacy-to-effectiveness (E2E) clinical trials.Pharmacogenetics in reproductive and perinatal medicine.HER2 amplification level is not a prognostic factor for HER2-positive breast cancer with trastuzumab-based adjuvant treatment: a systematic review and meta-analysis.High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical TrialImpact of HER2 copy number in IHC2+/FISH-amplified breast cancer on outcome of adjuvant trastuzumab treatment in a large UK cancer network.The updated ASCO/CAP guideline recommendations for HER2 testing in the management of invasive breast cancer: a critical review of their implications for routine practice.HER2 assessment by silver in situ hybridization: where are we now?HER2 testing and its predictive utility in anti-HER2 breast cancer therapy.HER2-positive breast cancer is lost in translation: time for patient-centered research.Resistance to Targeted Therapies in Breast Cancer.'Non-classical' HER2 FISH results in breast cancer: a multi-institutional study.KRAS, BRAF, EGFR and HER2 gene status in a Spanish population of colorectal cancer.Lack of independent prognostic and predictive value of centromere 17 copy number changes in breast cancer patients with known HER2 and TOP2A status.SHOULD FISH TEST BE PERFORMED TO ALL PATIENTS WITH BREAST CANCER?Breast carcinomas with low amplified/equivocal HER2 by Ish: potential supporting role of multiplex ligation-dependent probe amplification.
P2860
Q24200192-E706755C-7E21-4C81-9EAA-95AEC5FA3E67Q27006811-2228ACBA-F45F-46D8-BC09-8973B6A43239Q27015506-718E9005-A1CE-4074-BB73-3B97BF86FA01Q30996906-19BA298B-CABA-4D9F-80C0-2476BAF0EEE8Q33779412-297B367E-D646-4F4C-87E3-239D1F9451A8Q33862786-3496DE8B-0DE5-421F-90D2-5B4128566E6BQ34084063-8164FAF7-33D5-409F-AADB-F66E463836B2Q34194672-AC3912E2-0278-460D-9103-8527B7868DEEQ34344198-9DBE04C8-FC23-4783-9E34-683007F359A5Q34669425-1099DD7C-51F4-4790-99F6-59B5D57E94D3Q34855870-C879CCFB-3F12-417F-9DB1-53B76302EC24Q35185733-6FCBE23D-300D-4506-9EF9-49EB4089BE39Q35195417-169E8E5E-1F1A-4BE6-8E2B-5005B311CCF0Q35239634-C801CAFF-E566-4A32-857A-D0E480D4A852Q35904441-2C927810-98BA-420E-9FE5-720241B60BFEQ35926270-976BE14F-8F37-40DC-8C81-A5D495513FB7Q36051500-9B5190CB-77F3-4B2D-B14D-2FB6625DD379Q36087126-05635D4E-2347-40D7-A642-6C9AA0B1B55DQ36110190-84B9F8DF-202C-4EAC-9BE5-F7A2F1E6E0A0Q36452222-8B0A9406-5C54-45C5-B415-4E87DE7C94ABQ36707771-34187661-4B37-435B-AC62-89D2506820CFQ36903047-117063F1-6457-4D5F-9424-93F05C9911B5Q37142882-D27A34AE-64DF-48C0-A0B4-9814983CA013Q37301435-8A6898B7-42A1-4EAD-8A16-FABEBBDC381EQ37444430-84209B47-0C63-4399-8B44-9CDC09CCEEBDQ37524053-EF6F5D06-1D4E-4B54-BF13-CC6F5F20121DQ37657531-D2FD5E21-492A-4AEC-8D9C-EDEDCFD0E86EQ37665397-728C8C3E-3884-45CF-A007-B79AAA1B7443Q37682595-91BC6B3A-FE57-47A0-BA8A-302603730E3BQ37711674-C3FC26C1-D4F4-4D92-85D6-287DBA0FE04AQ38175061-2CE3F089-D6FF-4025-B2A7-E0365D29877BQ38314355-E7A59886-9249-4F22-AB8C-40352F53A20DQ38326102-318E33EE-30F2-4879-9979-4C9EEB036E7EQ38648765-3E5D4D42-5347-4084-9060-2D56AB53389CQ38748114-F2656BDF-DC49-4779-9950-4621900C1C1DQ39292642-D962C72E-C57C-40D0-85DD-2379C5F1E300Q39861972-ED4048C3-9D48-467E-984E-5F10EDBF88B8Q41133771-CD30FCF6-233D-48FC-9803-B784CCBDB7FCQ41866542-C01023BD-B641-4854-BF96-3E1AB322836DQ42377436-4F47A690-D8ED-4652-B894-1CC1FF2F69A7
P2860
Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: the HERA Trial.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 13 April 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Disease-free survival accordin ...... f trastuzumab: the HERA Trial.
@en
Disease-free survival accordin ...... f trastuzumab: the HERA Trial.
@nl
type
label
Disease-free survival accordin ...... f trastuzumab: the HERA Trial.
@en
Disease-free survival accordin ...... f trastuzumab: the HERA Trial.
@nl
prefLabel
Disease-free survival accordin ...... f trastuzumab: the HERA Trial.
@en
Disease-free survival accordin ...... f trastuzumab: the HERA Trial.
@nl
P2093
P2860
P50
P356
P1476
Disease-free survival accordin ...... f trastuzumab: the HERA Trial.
@en
P2093
Brian Leyland-Jones
Bruce Jordan
Josef Rueschoff
Marion Procter
Mark Abramovitz
Oliver Stoss
Richard D Gelber
Stella Dolci
Urania Dafni
Worta McCaskill-Stevens
P2860
P304
P356
10.1200/JCO.2008.19.7939
P407
P577
2009-04-13T00:00:00Z